DOCS
Doximity, Inc.43.80
-0.85-1.9%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
MFN delays detailed; growth acceleration eyed.
Q&A unpacked Q4's 4% growth caution as MFN policy deals delayed top-20 pharma signings and upfront budgets, but January bookings logged the best growth since IPO. Management eyes double-digit calendar '26 exit via upsell funds and late-year AI pharma product launch, tapping search/innovation budgets. They set 50% adjusted EBITDA margins as a floor for AI infra spends, with unit costs expected to improve. Peer check's 10,000 experts emerged as key trust differentiator. January bookings crushed it. Analysts probed competition and budgets; replies were direct yet guarded on FY27. Investors will track cal '26 ramp and AI monetization.
Key Stats
Market Cap
8.25BP/E (TTM)
35.04Basic EPS (TTM)
1.25Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
Doximity posted Q3 FY2026 revenue of $185.1M, up 10% y/y, with subscription revenue climbing 10% to $175.4M on new customers and 7% higher spend from existing ones; gross margin held at 90%. Operating income dipped to $71.9M from $79.9M y/y amid 54% surge in R&D to $34.6M, yet diluted EPS landed at $0.31 on 199.2M shares. Free cash flow hit $210.2M YTD (derived). Closed Pathway acquisition in July 2025 for $36.3M (cash/RSUs per Note 8), adding $17.0M goodwill and $18.7M developed technology (5-year life). Cash plus marketable securities stood at $735.1M post $417M buybacks, no debt. Ongoing litigation poses risks.
8-K
Q3 beats, CFO leave, $500M buyback
Doximity posted Q3 FY2026 revenue of $185.1M, up 10% year-over-year, with net income at $61.6M (33% margin) and Adjusted EBITDA of $111.4M (60% margin), fueled by record workflow engagement at 720,000 users and AI adoption over 300,000. CFO Anna Bryson took temporary medical leave effective February 3, 2026; CAO Siddharth Sitaram steps in as interim. Board authorized $500M stock repurchase.
8-K
Securities suit settled
Doximity settled its securities litigation for $31 million on December 24, 2025, fully funded by insurance with no admission of liability. The deal, pending court approval and stockholder notice, dismisses all claims against the company and named directors/officers. Risks loom if plaintiffs opt out. Settlement clears the deck.
8-K
Q2 revenue up 23%
10-Q
Q2 FY2026 results
Doximity crushed Q2 FY2026 ended September 30, 2025, with revenue jumping 23% y/y to $168.5M on subscription strength, while operating income soared 20% y/y to $63.7M and diluted EPS climbed to $0.31 from $0.22 (reconciles to 200.7M shares). Gross margin held steady at 90%, yet R&D and sales expenses rose on hiring and marketing push. Free cash flow hit $151.7M (operating cash $156.0M minus $4.3M capex); cash plus marketable securities stood at $878.4M despite $144.2M stock repurchases, with $279.8M authorized remaining. Closed Pathway acquisition in July 2025 for $36.3M (cash/RSUs), recognizing $17.0M goodwill and $18.7M developed technology (5-year life). Cash stays king. Litigation clouds persist.
IPO
Website
Employees
Sector
Industry
DCGO
DocGo Inc.
0.91-0.01
DH
Definitive Healthcare Corp.
2.29-0.01
DOCU
DocuSign, Inc.
67.58-0.61
DRIO
DarioHealth Corp.
12.05+0.05
GDRX
GoodRx Holdings, Inc.
2.76+0.05
HIMS
Hims & Hers Health, Inc.
36.86+0.61
HNGE
Hinge Health, Inc.
48.41-0.09
LFMD
LifeMD, Inc.
3.42+0.15
OPRX
OptimizeRx Corporation
12.77-0.41
TDOC
Teladoc Health, Inc.
7.41+0.07